Department: DRUG CHALLENGE
CAN YOU IDENTIFY these drugs indicated for managing diabetes? To find out, match each drug name in Section II with its brand name in Section I.
_____ 1. Ozempic (Novo Nordisk)
_____ 2. Fiasp (Novo Nordisk)
_____ 3. Admelog (Sanofi-Aventis)
a. insulin lispro injection. A “follow-on” rapid-acting (meal-time) insulin analog, this formulation is indicated to improve glycemic control in adults and pediatric patients 3 years and older with type 1 diabetes mellitus, and in adults with type 2 diabetes mellitus. It is available in both multidose vials and single-patient-use pens. This insulin lispro formulation is not considered a biosimilar product and is not interchangeable with other insulin lispro preparations; the prescriber should guide patients who are switching between insulin lispro formulations.
b. semaglutide. This drug is a new glucagon-like peptide 1 (GLP-1) receptor agonist indicated, along with diet and exercise, to treat patients with type 2 diabetes. It is administered subcutaneously via a single-patient-use pen as a once-weekly injection, which can be administered regardless of food intake and at any time of day. It should not be used in patients with a personal or family history of thyroid tumors. Common adverse reactions include nausea, vomiting, diarrhea, abdominal pain, and constipation.
c. insulin aspart injection. This new “follow-on” rapid-acting (meal-time) human insulin analog is formulated with l-arginine (an amino acid) and niacinamide (a B vitamin), which are intended to promote formula stabilization and faster absorption. Available in multidose vials or single-patient-use pens, this product is administered as a subcutaneous injection in the abdomen, upper arm, or thigh. It should be administered within 20 minutes after the start of a meal. As with other rapid-acting insulin analogs, monitor patients for signs and symptoms of hypoglycemia and hypokalemia. Never use an insulin pen for more than one patient.
ANSWERS: 1b, 2c, 3a